Innovative Albuvirtide-Based Combination Regimen in Critically Ill HIV-1-Infected Patients: Evidence of Viral Suppression and Safety Outcomes Article Swipe

PDF

Hu Caiqin , Zhou Xiaotang , He Lingling , Zhu Xueling , Cao Qing , Dai Bohao , Su Junwei , Liu Huiting , Qin Jia-ying , Wang Jingjing , Zhu Biao ·

YOU? · · 2025 · Open Access · · DOI: https://doi.org/10.21203/rs.3.rs-7981064/v1

Background To control HIV-1 viral load, reduce drug resistance, and maintain optimal immune function, albuvirtide (ABT) combined with antiretroviral therapy (ART) is used in designated AIDS hospitals in China. However, the standard weekly 320-mg ABT injection regimen poses adherence-related challenges. This study aimed to evaluate the safety and efficacy of an optimized ABT regimen in HIV-1-infected patients. Methods Twenty HIV-1-infected patients received ABT 320 mg intravenously for three consecutive days every four weeks, alongside their baseline ART regimens. Peripheral blood samples were collected to measure alanine aminotransferase (ALT), aspartate aminotransferase (AST), triglyceride (TAG), cholesterol, CD4 ⁺ T-cell counts, and HIV-RNA levels, and ABT concentrations (pre-dose and 2 hours after dose). Results All patients maintained high adherence and reported reduced psychological burden. No drug-related adverse events (e.g., injection-site reactions, hepatotoxicity, nephrotoxicity) were observed. Laboratory parameters remained stable, with no significant changes from baseline ( P > 0.05). Pharmacokinetic analysis demonstrated sustained therapeutic exposure, with mean trough concentrations of 4.71 mg/L, 3.83 mg/L, and 4.53 mg/L at Weeks 4, 8, and 12, respectively exceeding 50× the IC₉₀. The mean viral load decreased from 1.65 log ₁₀ copies/mL at baseline to 0.59 log ₁₀ copies/mL at Week 12 (mean reduction: 1.06 log₁₀ copies/mL; P = 0.0007). Among patients with baseline HIV-RNA > 20 copies/mL, the viral load decreased from 2.55 to 1.43 log ₁₀ copies/mL. Although both CD4 ⁺ and CD8 ⁺ T-cell counts increased, the changes were not statistically significant. Conclusion The innovative ABT regimen, administered every four weeks, demonstrated effective viral suppression and a favorable safety and tolerability profile. Sustained plasma drug concentrations above the PA-IC₉₀ support its potential as a promising long-acting antiretroviral agent with improved patient adherence and applicability for managing HIV-1. These findings suggest that this approach may offer a promising therapeutic option for treatment-refractory HIV-1 populations.

Related Topics

Medicine

Ranger Regiment (United Kingdom)

Concepts

Medicine Regimen Viral load Adverse effect Internal medicine Pharmacokinetics Critically ill Drug Immune system Pharmacodynamics CD8 Coronavirus disease 2019 (COVID-19) Pharmacology Triglyceride Pharmacotherapy Alanine aminotransferase Immunology Gastroenterology Trough level Viral disease Clinical trial

Metadata

Type: article
Landing Page: https://doi.org/10.21203/rs.3.rs-7981064/v1
PDF: https://www.researchsquare.com/article/rs-7981064/latest.pdf
OA Status: gold
References: 16
OpenAlex ID: https://openalex.org/W7106534615

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W7106534615

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.21203/rs.3.rs-7981064/v1

Digital Object Identifier
Title: Innovative Albuvirtide-Based Combination Regimen in Critically Ill HIV-1-Infected Patients: Evidence of Viral Suppression and Safety Outcomes

Work title
Type: article

OpenAlex work type
Publication year: 2025

Year of publication
Publication date: 2025-11-25

Full publication date if available
Authors: Hu Caiqin, Zhou Xiaotang, He Lingling, Zhu Xueling, Cao Qing, Dai Bohao, Su Junwei, Liu Huiting, Qin Jia-ying, Wang Jingjing, Zhu Biao

List of authors in order
Landing page: https://doi.org/10.21203/rs.3.rs-7981064/v1

Publisher landing page
PDF URL: https://www.researchsquare.com/article/rs-7981064/latest.pdf

Direct link to full text PDF
Open access: Yes

Whether a free full text is available
OA status: gold

Open access status per OpenAlex
OA URL: https://www.researchsquare.com/article/rs-7981064/latest.pdf

Direct OA link when available
Concepts: Medicine, Regimen, Viral load, Adverse effect, Internal medicine, Pharmacokinetics, Critically ill, Drug, Immune system, Pharmacodynamics, CD8, Coronavirus disease 2019 (COVID-19), Pharmacology, Triglyceride, Pharmacotherapy, Alanine aminotransferase, Immunology, Gastroenterology, Trough level, Viral disease, Clinical trial

Top concepts (fields/topics) attached by OpenAlex
Cited by: 0

Total citation count in OpenAlex
References (count): 16

Number of works referenced by this work

Full payload

id	https://openalex.org/W7106534615
doi	https://doi.org/10.21203/rs.3.rs-7981064/v1
ids.doi	https://doi.org/10.21203/rs.3.rs-7981064/v1
ids.openalex	https://openalex.org/W7106534615
fwci	0.0
type	article
title	Innovative Albuvirtide-Based Combination Regimen in Critically Ill HIV-1-Infected Patients: Evidence of Viral Suppression and Safety Outcomes
biblio.issue
biblio.volume
biblio.last_page
biblio.first_page
is_xpac	False
apc_list
apc_paid
concepts[0].id	https://openalex.org/C71924100
concepts[0].level	0
concepts[0].score	0.8660898804664612
concepts[0].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[0].display_name	Medicine
concepts[1].id	https://openalex.org/C2781413609
concepts[1].level	2
concepts[1].score	0.7952239513397217
concepts[1].wikidata	https://www.wikidata.org/wiki/Q7308373
concepts[1].display_name	Regimen
concepts[2].id	https://openalex.org/C142462285
concepts[2].level	3
concepts[2].score	0.7126410603523254
concepts[2].wikidata	https://www.wikidata.org/wiki/Q2528140
concepts[2].display_name	Viral load
concepts[3].id	https://openalex.org/C197934379
concepts[3].level	2
concepts[3].score	0.5690522789955139
concepts[3].wikidata	https://www.wikidata.org/wiki/Q2047938
concepts[3].display_name	Adverse effect
concepts[4].id	https://openalex.org/C126322002
concepts[4].level	1
concepts[4].score	0.5463473796844482
concepts[4].wikidata	https://www.wikidata.org/wiki/Q11180
concepts[4].display_name	Internal medicine
concepts[5].id	https://openalex.org/C112705442
concepts[5].level	2
concepts[5].score	0.46104684472084045
concepts[5].wikidata	https://www.wikidata.org/wiki/Q323936
concepts[5].display_name	Pharmacokinetics
concepts[6].id	https://openalex.org/C2991859549
concepts[6].level	2
concepts[6].score	0.40653151273727417
concepts[6].wikidata	https://www.wikidata.org/wiki/Q679690
concepts[6].display_name	Critically ill
concepts[7].id	https://openalex.org/C2780035454
concepts[7].level	2
concepts[7].score	0.40231817960739136
concepts[7].wikidata	https://www.wikidata.org/wiki/Q8386
concepts[7].display_name	Drug
concepts[8].id	https://openalex.org/C8891405
concepts[8].level	2
concepts[8].score	0.39139628410339355
concepts[8].wikidata	https://www.wikidata.org/wiki/Q1059
concepts[8].display_name	Immune system
concepts[9].id	https://openalex.org/C111113717
concepts[9].level	3
concepts[9].score	0.3800755739212036
concepts[9].wikidata	https://www.wikidata.org/wiki/Q725307
concepts[9].display_name	Pharmacodynamics
concepts[10].id	https://openalex.org/C167672396
concepts[10].level	3
concepts[10].score	0.3798244893550873
concepts[10].wikidata	https://www.wikidata.org/wiki/Q417800
concepts[10].display_name	CD8
concepts[11].id	https://openalex.org/C3008058167
concepts[11].level	4
concepts[11].score	0.3437005877494812
concepts[11].wikidata	https://www.wikidata.org/wiki/Q84263196
concepts[11].display_name	Coronavirus disease 2019 (COVID-19)
concepts[12].id	https://openalex.org/C98274493
concepts[12].level	1
concepts[12].score	0.33550921082496643
concepts[12].wikidata	https://www.wikidata.org/wiki/Q128406
concepts[12].display_name	Pharmacology
concepts[13].id	https://openalex.org/C2778913445
concepts[13].level	3
concepts[13].score	0.32754307985305786
concepts[13].wikidata	https://www.wikidata.org/wiki/Q186319
concepts[13].display_name	Triglyceride
concepts[14].id	https://openalex.org/C500440147
concepts[14].level	2
concepts[14].score	0.31014251708984375
concepts[14].wikidata	https://www.wikidata.org/wiki/Q701216
concepts[14].display_name	Pharmacotherapy
concepts[15].id	https://openalex.org/C2992872382
concepts[15].level	2
concepts[15].score	0.3010818660259247
concepts[15].wikidata	https://www.wikidata.org/wiki/Q305481
concepts[15].display_name	Alanine aminotransferase
concepts[16].id	https://openalex.org/C203014093
concepts[16].level	1
concepts[16].score	0.29404541850090027
concepts[16].wikidata	https://www.wikidata.org/wiki/Q101929
concepts[16].display_name	Immunology
concepts[17].id	https://openalex.org/C90924648
concepts[17].level	1
concepts[17].score	0.29206496477127075
concepts[17].wikidata	https://www.wikidata.org/wiki/Q120569
concepts[17].display_name	Gastroenterology
concepts[18].id	https://openalex.org/C31785415
concepts[18].level	4
concepts[18].score	0.27939993143081665
concepts[18].wikidata	https://www.wikidata.org/wiki/Q7846541
concepts[18].display_name	Trough level
concepts[19].id	https://openalex.org/C2780727368
concepts[19].level	3
concepts[19].score	0.27170851826667786
concepts[19].wikidata	https://www.wikidata.org/wiki/Q1928978
concepts[19].display_name	Viral disease
concepts[20].id	https://openalex.org/C535046627
concepts[20].level	2
concepts[20].score	0.26346468925476074
concepts[20].wikidata	https://www.wikidata.org/wiki/Q30612
concepts[20].display_name	Clinical trial
keywords[0].id	https://openalex.org/keywords/regimen
keywords[0].score	0.7952239513397217
keywords[0].display_name	Regimen
keywords[1].id	https://openalex.org/keywords/viral-load
keywords[1].score	0.7126410603523254
keywords[1].display_name	Viral load
keywords[2].id	https://openalex.org/keywords/adverse-effect
keywords[2].score	0.5690522789955139
keywords[2].display_name	Adverse effect
keywords[3].id	https://openalex.org/keywords/pharmacokinetics
keywords[3].score	0.46104684472084045
keywords[3].display_name	Pharmacokinetics
keywords[4].id	https://openalex.org/keywords/critically-ill
keywords[4].score	0.40653151273727417
keywords[4].display_name	Critically ill
keywords[5].id	https://openalex.org/keywords/drug
keywords[5].score	0.40231817960739136
keywords[5].display_name	Drug
keywords[6].id	https://openalex.org/keywords/immune-system
keywords[6].score	0.39139628410339355
keywords[6].display_name	Immune system
keywords[7].id	https://openalex.org/keywords/pharmacodynamics
keywords[7].score	0.3800755739212036
keywords[7].display_name	Pharmacodynamics
language
locations[0].id	doi:10.21203/rs.3.rs-7981064/v1
locations[0].is_oa	True
locations[0].source
locations[0].license	cc-by
locations[0].pdf_url	https://www.researchsquare.com/article/rs-7981064/latest.pdf
locations[0].version	acceptedVersion
locations[0].raw_type	posted-content
locations[0].license_id	https://openalex.org/licenses/cc-by
locations[0].is_accepted	True
locations[0].is_published	False
locations[0].raw_source_name
locations[0].landing_page_url	https://doi.org/10.21203/rs.3.rs-7981064/v1
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A3200616467
authorships[0].author.orcid
authorships[0].author.display_name	Hu Caiqin
authorships[0].countries	CN
authorships[0].affiliations[0].institution_ids	https://openalex.org/I4210166576
authorships[0].affiliations[0].raw_affiliation_string	First Affiliated Hospital Zhejiang University
authorships[0].institutions[0].id	https://openalex.org/I4210166576
authorships[0].institutions[0].ror	https://ror.org/https://ror.org/05m1p5x56
authorships[0].institutions[0].type	healthcare
authorships[0].institutions[0].lineage	https://openalex.org/I4210166576
authorships[0].institutions[0].country_code	CN
authorships[0].institutions[0].display_name	First Affiliated Hospital Zhejiang University
authorships[0].author_position	first
authorships[0].raw_author_name	Hu Caiqin
authorships[0].is_corresponding	True
authorships[0].raw_affiliation_strings	First Affiliated Hospital Zhejiang University
authorships[1].author.id	https://openalex.org/A2359844546
authorships[1].author.orcid
authorships[1].author.display_name	Zhou Xiaotang
authorships[1].countries	CN
authorships[1].affiliations[0].institution_ids	https://openalex.org/I4210166576
authorships[1].affiliations[0].raw_affiliation_string	First Affiliated Hospital Zhejiang University
authorships[1].institutions[0].id	https://openalex.org/I4210166576
authorships[1].institutions[0].ror	https://ror.org/https://ror.org/05m1p5x56
authorships[1].institutions[0].type	healthcare
authorships[1].institutions[0].lineage	https://openalex.org/I4210166576
authorships[1].institutions[0].country_code	CN
authorships[1].institutions[0].display_name	First Affiliated Hospital Zhejiang University
authorships[1].author_position	middle
authorships[1].raw_author_name	Zhou Xiaotang
authorships[1].is_corresponding	False
authorships[1].raw_affiliation_strings	First Affiliated Hospital Zhejiang University
authorships[2].author.id	https://openalex.org/A2664042050
authorships[2].author.orcid
authorships[2].author.display_name	He Lingling
authorships[2].countries	JP
authorships[2].affiliations[0].institution_ids	https://openalex.org/I4210126637
authorships[2].affiliations[0].raw_affiliation_string	Zhuji People's Hospital
authorships[2].institutions[0].id	https://openalex.org/I4210126637
authorships[2].institutions[0].ror	https://ror.org/https://ror.org/031jw0220
authorships[2].institutions[0].type	healthcare
authorships[2].institutions[0].lineage	https://openalex.org/I4210126637
authorships[2].institutions[0].country_code	JP
authorships[2].institutions[0].display_name	Uji Hospital
authorships[2].author_position	middle
authorships[2].raw_author_name	He Lingling
authorships[2].is_corresponding	False
authorships[2].raw_affiliation_strings	Zhuji People's Hospital
authorships[3].author.id	https://openalex.org/A2371183216
authorships[3].author.orcid
authorships[3].author.display_name	Zhu Xueling
authorships[3].countries	CN
authorships[3].affiliations[0].institution_ids	https://openalex.org/I4210166576
authorships[3].affiliations[0].raw_affiliation_string	First Affiliated Hospital Zhejiang University
authorships[3].institutions[0].id	https://openalex.org/I4210166576
authorships[3].institutions[0].ror	https://ror.org/https://ror.org/05m1p5x56
authorships[3].institutions[0].type	healthcare
authorships[3].institutions[0].lineage	https://openalex.org/I4210166576
authorships[3].institutions[0].country_code	CN
authorships[3].institutions[0].display_name	First Affiliated Hospital Zhejiang University
authorships[3].author_position	middle
authorships[3].raw_author_name	Zhu Xueling
authorships[3].is_corresponding	False
authorships[3].raw_affiliation_strings	First Affiliated Hospital Zhejiang University
authorships[4].author.id	https://openalex.org/A2012499503
authorships[4].author.orcid
authorships[4].author.display_name	Cao Qing
authorships[4].countries	CN
authorships[4].affiliations[0].institution_ids	https://openalex.org/I4210166576
authorships[4].affiliations[0].raw_affiliation_string	First Affiliated Hospital Zhejiang University
authorships[4].institutions[0].id	https://openalex.org/I4210166576
authorships[4].institutions[0].ror	https://ror.org/https://ror.org/05m1p5x56
authorships[4].institutions[0].type	healthcare
authorships[4].institutions[0].lineage	https://openalex.org/I4210166576
authorships[4].institutions[0].country_code	CN
authorships[4].institutions[0].display_name	First Affiliated Hospital Zhejiang University
authorships[4].author_position	middle
authorships[4].raw_author_name	Cao Qing
authorships[4].is_corresponding	False
authorships[4].raw_affiliation_strings	First Affiliated Hospital Zhejiang University
authorships[5].author.id
authorships[5].author.orcid
authorships[5].author.display_name	Dai Bohao
authorships[5].countries	CN
authorships[5].affiliations[0].institution_ids	https://openalex.org/I4210166576
authorships[5].affiliations[0].raw_affiliation_string	First Affiliated Hospital Zhejiang University
authorships[5].institutions[0].id	https://openalex.org/I4210166576
authorships[5].institutions[0].ror	https://ror.org/https://ror.org/05m1p5x56
authorships[5].institutions[0].type	healthcare
authorships[5].institutions[0].lineage	https://openalex.org/I4210166576
authorships[5].institutions[0].country_code	CN
authorships[5].institutions[0].display_name	First Affiliated Hospital Zhejiang University
authorships[5].author_position	middle
authorships[5].raw_author_name	Dai Bohao
authorships[5].is_corresponding	False
authorships[5].raw_affiliation_strings	First Affiliated Hospital Zhejiang University
authorships[6].author.id	https://openalex.org/A2105189495
authorships[6].author.orcid
authorships[6].author.display_name	Su Junwei
authorships[6].countries	CN
authorships[6].affiliations[0].institution_ids	https://openalex.org/I4210166576
authorships[6].affiliations[0].raw_affiliation_string	First Affiliated Hospital Zhejiang University
authorships[6].institutions[0].id	https://openalex.org/I4210166576
authorships[6].institutions[0].ror	https://ror.org/https://ror.org/05m1p5x56
authorships[6].institutions[0].type	healthcare
authorships[6].institutions[0].lineage	https://openalex.org/I4210166576
authorships[6].institutions[0].country_code	CN
authorships[6].institutions[0].display_name	First Affiliated Hospital Zhejiang University
authorships[6].author_position	middle
authorships[6].raw_author_name	Su Junwei
authorships[6].is_corresponding	False
authorships[6].raw_affiliation_strings	First Affiliated Hospital Zhejiang University
authorships[7].author.id	https://openalex.org/A2360526162
authorships[7].author.orcid
authorships[7].author.display_name	Liu Huiting
authorships[7].countries	CN
authorships[7].affiliations[0].institution_ids	https://openalex.org/I4210166576
authorships[7].affiliations[0].raw_affiliation_string	First Affiliated Hospital Zhejiang University
authorships[7].institutions[0].id	https://openalex.org/I4210166576
authorships[7].institutions[0].ror	https://ror.org/https://ror.org/05m1p5x56
authorships[7].institutions[0].type	healthcare
authorships[7].institutions[0].lineage	https://openalex.org/I4210166576
authorships[7].institutions[0].country_code	CN
authorships[7].institutions[0].display_name	First Affiliated Hospital Zhejiang University
authorships[7].author_position	middle
authorships[7].raw_author_name	Liu Huiting
authorships[7].is_corresponding	False
authorships[7].raw_affiliation_strings	First Affiliated Hospital Zhejiang University
authorships[8].author.id	https://openalex.org/A2378835174
authorships[8].author.orcid
authorships[8].author.display_name	Qin Jia-ying
authorships[8].countries	CN
authorships[8].affiliations[0].institution_ids	https://openalex.org/I4210166576
authorships[8].affiliations[0].raw_affiliation_string	First Affiliated Hospital Zhejiang University
authorships[8].institutions[0].id	https://openalex.org/I4210166576
authorships[8].institutions[0].ror	https://ror.org/https://ror.org/05m1p5x56
authorships[8].institutions[0].type	healthcare
authorships[8].institutions[0].lineage	https://openalex.org/I4210166576
authorships[8].institutions[0].country_code	CN
authorships[8].institutions[0].display_name	First Affiliated Hospital Zhejiang University
authorships[8].author_position	middle
authorships[8].raw_author_name	Qin Jiaying
authorships[8].is_corresponding	False
authorships[8].raw_affiliation_strings	First Affiliated Hospital Zhejiang University
authorships[9].author.id	https://openalex.org/A1196994367
authorships[9].author.orcid
authorships[9].author.display_name	Wang Jingjing
authorships[9].countries	CN
authorships[9].affiliations[0].institution_ids	https://openalex.org/I4210166576
authorships[9].affiliations[0].raw_affiliation_string	First Affiliated Hospital Zhejiang University
authorships[9].institutions[0].id	https://openalex.org/I4210166576
authorships[9].institutions[0].ror	https://ror.org/https://ror.org/05m1p5x56
authorships[9].institutions[0].type	healthcare
authorships[9].institutions[0].lineage	https://openalex.org/I4210166576
authorships[9].institutions[0].country_code	CN
authorships[9].institutions[0].display_name	First Affiliated Hospital Zhejiang University
authorships[9].author_position	middle
authorships[9].raw_author_name	Wang Jingjing
authorships[9].is_corresponding	False
authorships[9].raw_affiliation_strings	First Affiliated Hospital Zhejiang University
authorships[10].author.id	https://openalex.org/A2039043727
authorships[10].author.orcid
authorships[10].author.display_name	Zhu Biao
authorships[10].countries	CN
authorships[10].affiliations[0].institution_ids	https://openalex.org/I4210166576
authorships[10].affiliations[0].raw_affiliation_string	First Affiliated Hospital Zhejiang University
authorships[10].institutions[0].id	https://openalex.org/I4210166576
authorships[10].institutions[0].ror	https://ror.org/https://ror.org/05m1p5x56
authorships[10].institutions[0].type	healthcare
authorships[10].institutions[0].lineage	https://openalex.org/I4210166576
authorships[10].institutions[0].country_code	CN
authorships[10].institutions[0].display_name	First Affiliated Hospital Zhejiang University
authorships[10].author_position	last
authorships[10].raw_author_name	Zhu Biao
authorships[10].is_corresponding	False
authorships[10].raw_affiliation_strings	First Affiliated Hospital Zhejiang University
has_content.pdf	True
has_content.grobid_xml	False
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://www.researchsquare.com/article/rs-7981064/latest.pdf
open_access.oa_status	gold
open_access.any_repository_has_fulltext	False
created_date	2025-11-25T00:00:00
display_name	Innovative Albuvirtide-Based Combination Regimen in Critically Ill HIV-1-Infected Patients: Evidence of Viral Suppression and Safety Outcomes
has_fulltext	False
is_retracted	False
updated_date	2025-11-27T01:12:40.094763
primary_topic
cited_by_count	0
locations_count	1
best_oa_location.id	doi:10.21203/rs.3.rs-7981064/v1
best_oa_location.is_oa	True
best_oa_location.source
best_oa_location.license	cc-by
best_oa_location.pdf_url	https://www.researchsquare.com/article/rs-7981064/latest.pdf
best_oa_location.version	acceptedVersion
best_oa_location.raw_type	posted-content
best_oa_location.license_id	https://openalex.org/licenses/cc-by
best_oa_location.is_accepted	True
best_oa_location.is_published	False
best_oa_location.raw_source_name
best_oa_location.landing_page_url	https://doi.org/10.21203/rs.3.rs-7981064/v1
primary_location.id	doi:10.21203/rs.3.rs-7981064/v1
primary_location.is_oa	True
primary_location.source
primary_location.license	cc-by
primary_location.pdf_url	https://www.researchsquare.com/article/rs-7981064/latest.pdf
primary_location.version	acceptedVersion
primary_location.raw_type	posted-content
primary_location.license_id	https://openalex.org/licenses/cc-by
primary_location.is_accepted	True
primary_location.is_published	False
primary_location.raw_source_name
primary_location.landing_page_url	https://doi.org/10.21203/rs.3.rs-7981064/v1
publication_date	2025-11-25
publication_year	2025
referenced_works	https://openalex.org/W4380433627, https://openalex.org/W4327584548, https://openalex.org/W3037133507, https://openalex.org/W3111050887, https://openalex.org/W4280557686, https://openalex.org/W4281868785, https://openalex.org/W3011670145, https://openalex.org/W4409567264, https://openalex.org/W2260219149, https://openalex.org/W4307710231, https://openalex.org/W4410494135, https://openalex.org/W3004741911, https://openalex.org/W3201874739, https://openalex.org/W4388561392, https://openalex.org/W3197641636, https://openalex.org/W3106980473
referenced_works_count	16
abstract_inverted_index.(	143
abstract_inverted_index.2	107
abstract_inverted_index.=	202
abstract_inverted_index.a	253, 270, 292
abstract_inverted_index.12	195
abstract_inverted_index.20	210
abstract_inverted_index.4,	167
abstract_inverted_index.8,	168
abstract_inverted_index.No	122
abstract_inverted_index.To	2
abstract_inverted_index.an	51
abstract_inverted_index.as	269
abstract_inverted_index.at	165, 186, 193
abstract_inverted_index.in	24, 28, 55
abstract_inverted_index.is	22
abstract_inverted_index.mg	65
abstract_inverted_index.no	138
abstract_inverted_index.of	50, 157
abstract_inverted_index.to	44, 84, 188, 218
abstract_inverted_index.12,	170
abstract_inverted_index.320	64
abstract_inverted_index.ABT	35, 53, 63, 103, 242
abstract_inverted_index.ART	77
abstract_inverted_index.All	112
abstract_inverted_index.CD4	95, 225
abstract_inverted_index.CD8	228
abstract_inverted_index.The	176, 240
abstract_inverted_index.and	10, 48, 99, 102, 106, 117, 162, 169, 227, 252, 256, 279
abstract_inverted_index.for	67, 281, 296
abstract_inverted_index.its	267
abstract_inverted_index.log	183, 190, 220
abstract_inverted_index.may	290
abstract_inverted_index.not	236
abstract_inverted_index.the	31, 46, 174, 212, 233, 264
abstract_inverted_index.>	145, 209
abstract_inverted_index.0.59	189
abstract_inverted_index.1.06	198
abstract_inverted_index.1.43	219
abstract_inverted_index.1.65	182
abstract_inverted_index.2.55	217
abstract_inverted_index.3.83	160
abstract_inverted_index.4.53	163
abstract_inverted_index.4.71	158
abstract_inverted_index.50×	173
abstract_inverted_index.AIDS	26
abstract_inverted_index.This	41
abstract_inverted_index.Week	194
abstract_inverted_index.both	224
abstract_inverted_index.days	70
abstract_inverted_index.drug	8, 261
abstract_inverted_index.four	72, 246
abstract_inverted_index.from	141, 181, 216
abstract_inverted_index.high	115
abstract_inverted_index.load	179, 214
abstract_inverted_index.mean	154, 177
abstract_inverted_index.mg/L	164
abstract_inverted_index.that	287
abstract_inverted_index.this	288
abstract_inverted_index.used	23
abstract_inverted_index.were	82, 131, 235
abstract_inverted_index.with	18, 137, 153, 206, 275
abstract_inverted_index.(ABT)	16
abstract_inverted_index.(ART)	21
abstract_inverted_index.(mean	196
abstract_inverted_index.Among	204
abstract_inverted_index.HIV-1	4, 298
abstract_inverted_index.These	284
abstract_inverted_index.Weeks	166
abstract_inverted_index.above	263
abstract_inverted_index.after	109
abstract_inverted_index.agent	274
abstract_inverted_index.aimed	43
abstract_inverted_index.blood	80
abstract_inverted_index.every	71, 245
abstract_inverted_index.hours	108
abstract_inverted_index.load,	6
abstract_inverted_index.mg/L,	159, 161
abstract_inverted_index.offer	291
abstract_inverted_index.poses	38
abstract_inverted_index.study	42
abstract_inverted_index.their	75
abstract_inverted_index.three	68
abstract_inverted_index.viral	5, 178, 213, 250
abstract_inverted_index.(ALT),	88
abstract_inverted_index.(AST),	91
abstract_inverted_index.(TAG),	93
abstract_inverted_index.(e.g.,	126
abstract_inverted_index.0.05).	146
abstract_inverted_index.320-mg	34
abstract_inverted_index.China.	29
abstract_inverted_index.HIV-1.	283
abstract_inverted_index.T-cell	97, 230
abstract_inverted_index.Twenty	59
abstract_inverted_index.counts	231
abstract_inverted_index.dose).	110
abstract_inverted_index.events	125
abstract_inverted_index.immune	13
abstract_inverted_index.option	295
abstract_inverted_index.plasma	260
abstract_inverted_index.reduce	7
abstract_inverted_index.safety	47, 255
abstract_inverted_index.trough	155
abstract_inverted_index.weekly	33
abstract_inverted_index.weeks,	73, 247
abstract_inverted_index.HIV-RNA	100, 208
abstract_inverted_index.Methods	58
abstract_inverted_index.Results	111
abstract_inverted_index.adverse	124
abstract_inverted_index.alanine	86
abstract_inverted_index.burden.	121
abstract_inverted_index.changes	140, 234
abstract_inverted_index.control	3
abstract_inverted_index.counts,	98
abstract_inverted_index.levels,	101
abstract_inverted_index.measure	85
abstract_inverted_index.optimal	12
abstract_inverted_index.patient	277
abstract_inverted_index.reduced	119
abstract_inverted_index.regimen	37, 54
abstract_inverted_index.samples	81
abstract_inverted_index.stable,	136
abstract_inverted_index.suggest	286
abstract_inverted_index.support	266
abstract_inverted_index.therapy	20
abstract_inverted_index.0.0007).	203
abstract_inverted_index.Although	223
abstract_inverted_index.However,	30
abstract_inverted_index.analysis	148
abstract_inverted_index.approach	289
abstract_inverted_index.baseline	76, 142, 187, 207
abstract_inverted_index.combined	17
abstract_inverted_index.efficacy	49
abstract_inverted_index.evaluate	45
abstract_inverted_index.findings	285
abstract_inverted_index.improved	276
abstract_inverted_index.maintain	11
abstract_inverted_index.managing	282
abstract_inverted_index.patients	61, 113, 205
abstract_inverted_index.profile.	258
abstract_inverted_index.received	62
abstract_inverted_index.regimen,	243
abstract_inverted_index.remained	135
abstract_inverted_index.reported	118
abstract_inverted_index.standard	32
abstract_inverted_index.(pre-dose	105
abstract_inverted_index.IC₉₀.	175
abstract_inverted_index.Sustained	259
abstract_inverted_index.adherence	116, 278
abstract_inverted_index.alongside	74
abstract_inverted_index.aspartate	89
abstract_inverted_index.collected	83
abstract_inverted_index.copies/mL	185, 192
abstract_inverted_index.decreased	180, 215
abstract_inverted_index.effective	249
abstract_inverted_index.exceeding	172
abstract_inverted_index.exposure,	152
abstract_inverted_index.favorable	254
abstract_inverted_index.function,	14
abstract_inverted_index.hospitals	27
abstract_inverted_index.injection	36
abstract_inverted_index.log₁₀	199
abstract_inverted_index.observed.	132
abstract_inverted_index.optimized	52
abstract_inverted_index.patients.	57
abstract_inverted_index.potential	268
abstract_inverted_index.promising	271, 293
abstract_inverted_index.regimens.	78
abstract_inverted_index.sustained	150
abstract_inverted_index.Background	1
abstract_inverted_index.Conclusion	239
abstract_inverted_index.Laboratory	133
abstract_inverted_index.Peripheral	79
abstract_inverted_index.copies/mL,	211
abstract_inverted_index.copies/mL.	222
abstract_inverted_index.copies/mL;	200
abstract_inverted_index.designated	25
abstract_inverted_index.increased,	232
abstract_inverted_index.innovative	241
abstract_inverted_index.maintained	114
abstract_inverted_index.parameters	134
abstract_inverted_index.reactions,	128
abstract_inverted_index.reduction:	197
abstract_inverted_index.PA-IC₉₀	265
abstract_inverted_index.albuvirtide	15
abstract_inverted_index.challenges.	40
abstract_inverted_index.consecutive	69
abstract_inverted_index.long-acting	272
abstract_inverted_index.resistance,	9
abstract_inverted_index.significant	139
abstract_inverted_index.suppression	251
abstract_inverted_index.therapeutic	151, 294
abstract_inverted_index.<sup>+</sup>	96, 226, 229
abstract_inverted_index.administered	244
abstract_inverted_index.cholesterol,	94
abstract_inverted_index.demonstrated	149, 248
abstract_inverted_index.drug-related	123
abstract_inverted_index.populations.	299
abstract_inverted_index.respectively	171
abstract_inverted_index.significant.	238
abstract_inverted_index.tolerability	257
abstract_inverted_index.triglyceride	92
abstract_inverted_index.<sub>10</sub>	184, 191, 221
abstract_inverted_index.applicability	280
abstract_inverted_index.intravenously	66
abstract_inverted_index.psychological	120
abstract_inverted_index.statistically	237
abstract_inverted_index.HIV-1-infected	56, 60
abstract_inverted_index.antiretroviral	19, 273
abstract_inverted_index.concentrations	104, 156, 262
abstract_inverted_index.injection-site	127
abstract_inverted_index.Pharmacokinetic	147
abstract_inverted_index.hepatotoxicity,	129
abstract_inverted_index.nephrotoxicity)	130
abstract_inverted_index.aminotransferase	87, 90
abstract_inverted_index.adherence-related	39
abstract_inverted_index.<italic>P</italic>	144, 201
abstract_inverted_index.treatment-refractory	297
abstract_inverted_index.<title>Abstract</title>	0
cited_by_percentile_year
countries_distinct_count	2
institutions_distinct_count	11
citation_normalized_percentile